Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial (GATB), is a mitochondrial protein-coding enzyme that serves as the B subunit of the *glutamyl-tRNA(Gln) amidotransferase* (Glu-AdT, also known as the GatCAB complex) [3][1]. This multimeric complex is essential for the formation of correctly charged glutaminyl-tRNA(Gln) in mitochondria via a transamidation reaction that modifies misacylated glutamyl-tRNA(Gln), thereby ensuring fidelity during mitochondrial protein translation[1][3]. GATB, together with GatA and GatC, catalyzes the conversion of Glu-tRNA(Gln) to Gln-tRNA(Gln) in the presence of glutamine and ATP[3][1][4]. GATB has structural homology with Pet112-like proteins, which are conserved from bacteria to humans and are essential for mitochondrial function[1]. Pathogenic mutations in GATB disrupt mitochondrial translation, causing combined oxidative phosphorylation deficiency and other severe mitochondrial translation disorders[3][4]. GATB is not a direct pharmacological drug target, and no interacting drugs or mechanisms of action are currently reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial (GATB).